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Summary
Interleukin 1, one of the first cytokines discovered in the
1980s, and a potent mediator of fever, pain and inflam-
mation, is at present experiencing a revival in biology and
medicine. Whereas the mechanism of activation and secre-
tion of interleukin 1β, which critically regulates the func-
tion of this molecule, has remained mysterious for some 30
years following its discovery, the identification of a new
cytoplasmic complex of proteins regulating IL-1β activa-
tion and secretion has carried our understanding of the role
of IL1 in biology and disease one big step further. The
inflammasomes, recently identified innate immune com-
plexes that sense intracellular danger- (e.g. uric acid, ATP,
cytoplasmic DNA) or pathogen-associated molecular pat-
terns (e.g. muramyl dipeptide, flagellin, anthrax lethal tox-
in), are now known to be responsible for triggering inflam-
mation in response to several molecular patterns, including,
for example, uric acid, a danger-associated molecular pat-
tern and trigger of gout. Dysregulation of inflammasome
function is however also the cause of a family of genet-
ic autoinflammatory diseases known as cryopyrin-associ-
ated periodic syndromes (CAPS) characterised by recurrent
episodes of fever, urticarial-like skin lesions, systemic in-
flammation and arthritis. In mouse models recapitulating
mutations observed in CAPS, neutrophilic inflammation of
the skin is a cardinal feature, in a manner similar to several
autoinflammatory diseases with skin involvement such as
PAPA (pyoderma gangrenosum, acne and pyogenic arthrit-
is) and Schnitzler’s syndrome, in which IL-1β very prob-
ably plays a pathogenic role. In this article the role of the
inflammasome in IL-1 biology, autoinflammation and dis-
ease is reviewed, together with new avenues for the therapy
of these diseases.
Key words: inflammation; interleukin-1; innate immunity;
inflammasome; skin; fever
Introduction
In all types of tissue harmful stimuli such as trauma, patho-
gens or irritants induce a very complex response which is
called inflammation [1]. This fundamental and beneficial
process is required to remove the injurious stimulus and
to initiate the healing process aiming to restore tissue ho-
moeostasis. Although the quality and quantity of the in-
flammatory response depend on this stimulus and the con-
text, the very initial steps of the inflammatory response
are stereotyped as part of the innate immune response.
Since antiquity it has been known that acute inflammation,
which occurs within minutes or hours, is characterised by
the cardinal signs redness, heat, pain, swelling and loss of
function of the inflamed tissue [2]. However, inflamma-
tion can also become chronic and destructive, thus con-
tributing to the pathogenesis of chronic inflammatory dis-
eases. Recently evidence has accumulated showing that
low-grade chronic inflammation can cause or contribute to
the development of further diseases such as type 2 diabetes,
Alzheimer`s disease, artherosclerosis, and cancer [1, 3].
The skin is our largest organ, which is exposed to and pro-
tects the body from microbes, pathogens and several ir-
ritants. In most cases, inflammation of the skin represents
a protective process, e.g. upon injury or infection [4].
However, the skin can also be a site of excessive immune
responses resulting in chronic inflammation, autoimmunity
or autoiinflammation [5]. During the last ten years much
progress has been made in our understanding of the mo-
lecular and cellular mechanisms underlying the initiation
of an inflammatory response as part of the innate immune
response, be it beneficial or unwanted. The cytokines that
have proved essential at the onset of inflammation and dur-
ing an innate immune response include the proinflammat-
ory cytokine interleukin-1 (IL-1). This cytokine plays a
fundamental role in regulating systemic, but also certain
cutaneous inflammatory responses, and recently acquired
knowledge regarding the processing and activation of IL-1
beta (IL-1β) has taught us that it is implicated in the patho-
genesis of an emerging family of autoinflammatory dis-
eases and fever syndromes [4, 6].
In this review we describe the key advances in the un-
derstanding of the biology and pathophysiological role of
IL-1β with special focus on its contribution to autoinflam-
mation and its function in the skin.
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Interleukin-1 (IL-1)
IL-1 is an essential proinflammatory cytokine which pos-
sesses multiple properties and affects almost all cell types
[6–7]. It is a mediator of the acute phase of inflammation
by induction of local and systemic responses. Amongst oth-
ers IL-1 induces the expression of adhesion molecules on
endothelial cells, which are required for the infiltration of
the stressed tissue by inflammatory and immunocompetent
cells [6]. It also induces pain sensitivity, fever, vasodilation
and hypotension. IL-1 is strongly expressed by monocytes,
tissue macrophages and dendritic cells, but is also produced
by B lymphocytes, NK cells and epithelial cells [4, 6].
Both IL-1α and IL-1β exert their activity by binding and
signalling through IL-1 receptor type I (IL-1RI), which is
expressed by almost all cell types. The cytoplasmic part of
IL-1RI carries a toll/interleukin-1 receptor domain (TIR),
which is also found in toll-like receptors (TLR), pointing
to an important role of IL-1 in inflammation and innate im-
munity. Signal transduction by IL-1α and IL-1β requires re-
cruitment of the IL-1R accessory protein (IL-1RAcP), and
results in a series of incompletely understood phosphoryla-
tion and ubiquitination events, finally leading to activation
of nuclear factor ĸB (NF-ĸB) and signalling by the c-Jun
N-terminal kinase (JNK) and p38 mitogen-activated pro-
tein kinase (MAPK) pathway [8]. IL-1R type II (IL-1RII)
is a decoy receptor which lacks the TIR domain and cannot
signal. This receptor is also released from cells and can
thus also block the activity of IL-1 for neighbouring cells.
Agonists of IL-1RI are IL-1α and IL-1β, which are tran-
scribed from separate genes. In contrast, binding of IL-
R antagonist (IL-1Ra) to IL-1RI, which prevents binding
of IL-1α and IL-1β, does not result in recruitment of
IL-1RAcP and consequently leads to blockade of IL-1RI
signalling [9]. Recombinant IL-1Ra (Kineret, Anakinra®)
is used as a therapeutic in humans and has been approved
for the treatment of rheumatoid arthritis [10]. In recent
years it has emerged that Kineret shows clinical efficacy in
the treatment of a relatively broad spectrum of inflammat-
ory diseases without causing significant side effects, thus
demonstrating the central role IL-1 plays in these condi-
tions [7]. A disadvantage of Kineret is however its short
half-life in vivo, which requires daily injection of the drug.
This has been overcome by the recent development of addi-
tional inhibitors of IL-1 signalling, including a soluble re-
ceptor for IL-1 (Rilonacept, Arcalyst®), and a monoclonal
antibody to IL-1β (Canakinumab, Ilaris®).
Regulation of IL-1 production
Since IL-1 is such a potent and important cytokine, it is
not surprising that the generation of IL-1 activity is tightly
regulated at different levels. Evidence suggests that the ex-
pression of IL-1α, although it can be regulated, exists to
some extent at a constitutive level whereas in most cell
types expression of IL-1β is only detectable upon stimula-
tion [6, 11]. Expression of IL-1α and β is induced by ac-
tivation of the transcription factor NF-ĸB, for example by
exposure of macrophages and dendritic cells to the TLR4
agonist LPS (lipopolysaccharide) but also by IL-1 itself. In
addition, it has been shown that IL-1β mRNA can be very
unstable [12–13].
IL-1α and IL-1β are expressed as proproteins (proIL-1α
and proIL-1β). ProIL-1β cannot bind to IL-1RI, since re-
ceptor binding and activation requires prior proteolytic pro-
cessing of the propeptide, which is achieved in most cases
intracellularly by the protease caspase-1 [3]. However, us-
ing caspase-1-deficient mice it has been shown that under
certain conditions such as in neutrophil-dependent inflam-
mation, other proteases than caspase-1 are also able to
cleave and activate proIL-1β [14–15]. Nevertheless, cas-
pase-1 is considered to be the master protease required for
activation of IL1-β [3]. In contrast to proIL-1β, proIL-1α is
able to bind and activate IL-1RI although proteolysis of its
prosequence can enhance its biological activity [16]. Cell
lysis upon injury or trauma therefore generates IL-1 activ-
ity due to passive release of proIL-1α, whereas passively
released proIL-1β does not possess biological activity.
Most secreted proteins contain a signal peptide at the amino
terminus, which directs them through the classical endo-
plasmic reticulum/Golgi-dependent secretion pathway to
the extracellular space. In contrast, proIL-1α, proIL-1β and
several other proteins are leaderless, thus lacking a signal
peptide, and are secreted by a non-canonical pathway
called the unconventional protein secretion pathway [17].
The mechanism and regulation of unconventional secretion
is only poorly understood but it has recently been demon-
strated that caspase-1 activity is required for the secretion
of leaderless proteins [18–19].
As mentioned above, IL-1Ra blocks IL-1 activity. Al-
though IL-1Ra, IL-1α and IL-1β have a similar affinity to
IL-1RI, a large excess (100–1,000) of IL-1Ra over IL-1
is required for efficient blockade of receptor signalling in
vitro and in vivo [20].
Inflammasomes and regulation ofIL-1β activation
Figure 1
The inflammasomes. Several types of inflammasomes have been
described. Upon exposure to specific PAMPs/DAMPs, respective
inflammasomes are activated, leading to the proteolytic cleavage of
caspase-1 or -5 (CASP) and subsequent cleavage of pro-IL1β into
its active, secreted form.
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When proIL-1β synthesis is induced in circulating mono-
cytes, mature IL-1β is secreted because these cells contain
small amounts of active caspase-1 [21]. However, in all
other cell types caspase-1 is inactive in the absence of ac-
tivation signals, since this protease is synthesised as an in-
active proenzyme. Activation of the protease takes place
in recently identified innate immune complexes called in-
flammasomes [3]. The NLRP1 (nucleotide-binding do-
main, leucine-rich repeat-containing receptor protein, also
called NALP1) inflammasome was identified in 2002 in
a cell-free system of the myeloid cell line THP1 [22].
NLRP1 is the large backbone protein of the complex,
which upon assembly of the inflammasome complex binds
to caspase-5 and to ASC (apoptosis-associated speck-like
protein containing a caspase recruitment domain (CARD)).
The latter interacts with caspase-1, which brings both pro-
teases into close proximity, resulting in their activation
[22] (fig. 1). NLRP3, NLRP6 and AIM2 (absent in melan-
oma 2) can also bind caspase-1 via binding to the adaptor
protein ASC, whereas NLRC4 (Nod-like receptor family
CARD domain-containing proteins) interacts directly with
caspase-1 [23]. Assembly of these complexes results in oli-
gomerisation and subsequent activation of caspase-1. As a
consequence of this, active caspase-1 cleaves and activates
proIL-1β, but also the proinflammatory cytokine proIL-18.
Inflammasomes mediate the assembly and activation of
caspase-1 in response to selected proinflammatory stimuli,
including pathogen-associated molecular patterns (PAMPs)
such as LPS and endogenous damage-associated molecular
patterns (DAMPs) such as ATP. Four types of inflamma-
some complex that are activated upon encounter with dis-
tinct types of DAMPs and/or PAMPs have been charac-
terised. These are the Aim2, NLRP1, NLRP3 and NLRC4
inflammasomes (fig. 1). The Aim2 inflammasome is ac-
tivated by binding to viral and bacterial double-stranded
DNA resulting from intracellular pathogens, the NLRP1 in-
flammasome by muramyl dipeptide, and NLRC4 inflam-
masome by flagellin [23]. The NLRP3 inflammasome is
very probably the most important inflammasome since it
assembles in response to a large variety of PAMPs and
DAMPs, and its deficiency is already clearly associated
with immunological dysfunction in mice as well as disease
states in man. Since direct interaction of any of these ac-
tivators with NLRP3 could not be shown, indirect activ-
ation mechanisms have been suggested. Particulates such
as asbestos or crystals such as gout-causing monosodium
urate (MSU) or cholesterol are phagocytosed by macro-
phages [24–25]. However, their clearance is not efficient
and this results in lysosomal rupture, which, in turn, activ-
ates the NLRP3 inflammasome by an unknown mechanism
possibly involving cathepsins [25–26]. As all NLRP3 ac-
tivators induce the generation of reactive oxygen species
(ROS), it has been reported that this ROS production trig-
gers NLRP inflammasome activation [26]. Generation of
ROS induces dissociation of thioredoxin from thioredoxin-
interacting protein. Then the latter is able to bind NLRP3,
which induces inflammasome activation [27]. The predom-
inant source of ROS generated by danger signals is most
probably the mitochondria, which also controls inflamma-
some activation via the release of mitochondrial DNA
[28–29].
Inflammasome-dependent activation of caspase-1 induces
not only secretion of IL-1β and of IL-18 but also a lytic
form of cell death called pyroptosis [30–32]. In pyroptotic
cells caspase-1-dependent DNA fragmentation occurs,
though this does not require classical apoptotic caspases.
Pyroptosis is characterised by osmotic swelling of the cell,
which results in rupture of the plasma membrane. This in-
duces a strong inflammatory response through the release
of proinflammatory cytokines such as proIL-1α, but also
via spreading of ATP or other proinflammatory molecules
[33]. In contrast, apoptosis is immunologically silent.
The skin
At the body`s surface the skin prevents the loss of essential
body fluids and invasion of microbes and irritants. Its outer
layer is the epidermis, which consists mainly of kerat-
inocytes and contains few Langerhans cells, a specialised
form of DC (dentritic cells), and some pigment-producing
melanocytes [4–5]. Keratinocytes express several types of
keratin, proteins, which are expressed only in epithelia,
form intermediate filaments through assembly into bundles
and generate the toughness of the epidermis [34]. In the
underlying dermis several types of immune cell can be
found, such as macrophages, T cells and mast cells. They
are embedded in connective tissue, which is made up by a
mixture of extracellular matrix proteins produced by fibro-
blasts. The supply of nutrients of the whole skin is guar-
anteed by blood vessels in the dermis, the latter also con-
taining lymphatic vessels and nerve endings. In contrast to
the dermis, the epidermis is a constantly renewing tissue.
Proliferation of keratinocytes is restricted to the basal cell
layer, where stem cells and transit amplifying cells are loc-
ated. During an apoptosis-like process of terminal differ-
entiation, keratinocytes change their expression profile and
properties and migrate to the outer surface of the epidermis.
This generates several densely-packed layers of keratino-
cytes with dead, flat and keratin-filled corneocytes at the
surface, which form a protective envelope.
Under homoeostatic conditions, the skin is colonised by a
certain number and diversity of microorganisms on its sur-
face. The dynamic equilibrium between the epidermis and
microorganisms is regulated inter alia by sebocytes, which
are located in sebaceous glands within the dermis and pro-
duce anti-microbial lipids, as well as by the microbes them-
selves, which produce antibiotic and antifungal substances
as well as bacteriolytic enzymes. In addition, keratinocytes
express antimicrobial substances constitutively and upon
injury or infection, e.g. by stimulation of TLRs through
PAMPs and DAMPs [35]. Certain keratinocyte-derived an-
timicrobial peptides as well as cytokines can influence the
immunological properties of dendritic cells and T cells,
which are also influenced by stimulation of their own TLRs
and can activate adaptive immunity [4–5]. Therefore, on
the one hand the skin must ensure an efficient defence
against pathogens and immunosurveillance, and on the oth-
er hand the skin must minimise excessive immune re-
sponses which can result in disease states such as allergy,
chronic inflammation and autoimmunity.
Review article: Medical intelligence Swiss Med Wkly. 2012;142:w13590
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 3 of 10
IL-1 and inflammasomes inkeratinocytes
In contrast to macrophages and DCs, human primary ker-
atinocytes constitutively express inflammasome proteins as
well as proIL-1α, proIL-1β, and IL-1Ra [36–37]. Irradi-
ation with a physiological dose of UVB induces secretion
of proIL-1α and of mature and active IL-1β comparable to
the amount released by activated macrophages [36]. This
secretion requires expression of NLRP1, NLRP3, ASC,
caspase-4 and caspase-1, as well as caspase-1 and -4 activ-
ity [38]. Assembly of the inflammasome is dependent on
an increase in the concentration of cytoplasmic Ca2+. Most
importantly, caspase-1 expression is also required in vivo
in mice for the induction of an inflammatory response upon
UVB irradiation [36]. This points to an important role of
keratinocytes in the induction of sunburn and in innate im-
mune responses dependent on the inflammasome and IL-1.
Contact hypersensitivity (CH) is a frequent inflammatory
skin disease, also called eczema, which can be studied in
established mouse models of allergic contact dermatitis and
is based on an adaptive immune response to haptens [37].
In the first phase, application of haptens to the skin primes
T cells. A second hapten stimulus induces a local inflam-
matory response. This inflammation is most probably de-
pendent on the migration of Langerhans cells to lymph
nodes, subsequent antigen presentation and recruitment of
expanded T cells to the site of hapten application [5, 39].
Recent evidence provided by our group and others has now
shown that the earliest phase of sensitisation in CH critic-
ally depends on IL-1, ASC and NLRP3 expression and can
be inhibited by administration of IL-1Ra [37, 40–42]. IL-1
and the inflammasome is involved in sensing contact sens-
itizers in the skin and triggering an innate immune response
to these, which subsequently also very probably plays a
role in helping trigger the adaptive immune response to
contact sensitisers in the skin.
Figure 2
Current models of inflammasome activation involve K+ efflux,
release of reactive oxygen species (ROS) and mitochondrial DNA
(mtDNA) in the cytosol. Upon encounter of PAMPs/DAMPs
including microbes or crystals, the NLRP3–inflammasome is
activated and the resulting IL-1β release triggers localised
inflammatory responses. In contrast, the NLRP3–inflammasome is
constitutively activated, resulting in multi-organ involvement and
periodic fever in patients suffering from autoinflammatory disorders.
Keratinocytes express in vitro and in vivo the inflamma-
some component Aim2, a molecule which is important for
sensing intracellular double stranded DNA. Accordingly,
transfection of keratinocytes with double-stranded DNA in
vitro induces secretion of mature IL-1β in an Aim2- and
caspase-1-dependent manner [43–44]. Whether Aim2 ex-
pression is increased in skin biopsies of patients suffer-
ing from psoriasis, a chronic inflammatory skin disease,
is controverted. Interestingly, cytosolic DNA was detected
in keratinocytes of psoriatic lesions in contrast to healthy
skin, suggesting that cytosolic DNA may act as a DAMP
in psoriasis via activation of the Aim2 inflammasome [43].
The antimicrobial peptide LL-37, which can interact with
DNA and induce interferon alpha production by plasmacyt-
oid dendritic cells in psoriatic skin, can also block ac-
tivation of the Aim2 inflammasome by binding to and
neutralising cytosolic DNA. These data suggest that the
generation of IL-1 activity by the Aim2 inflammasome in
keratinocytes may contribute to the pathogenesis of psori-
asis.
An important illustration of the consequences of dysregu-
lated control of inflammasome activation for the skin and
inflammatory disease was recently provided by experi-
ments in mice where the NLRP3 gene mutation causing
CAPS (cryopyrin-associated periodic syndromes) was in-
troduced into mice. These mice that have a hyperactive in-
flammasome spontaneously develop a neutrophil rich in-
flammation of the skin with a TH17 dominant immune
response [45]. Interestingly, a redundant feature of inflam-
masome activation and IL-1β release in tissues thus ap-
pears to be the neutrophilic nature of the inflammatory in-
filtrates at sites of tissue inflammation. This feature is also
observed in several human autoinflammatory diseases.
Autoinflammatory diseases with skininvolvement
Autoinflammatory diseases are a relatively new category
of diseases distinct from allergic and autoimmune diseases
and characterised by seemingly unprovoked recurrent in-
flammation in the absence of evidence of circulating
autoantiobodies or an antigen-specific T cell response [46]
(fig. 2). Recently it has been shown that several mutations
in proteins of the inflammasome complex or proteins that
regulate the function of the inflammasome are associated
with autoinflammatory disease, including the cryopyrin-as-
sociated periodic syndromes such as Muckle-Wells syn-
drome, but also other diseases such as Schnitzler’s syn-
drome and Behçet’s disease in which IL-1 also appears to
play a critical role.
Cryopyrin-associated periodicsyndromes
Cryopirin-associated periodic syndromes (CAPS, OMIM/
606416) are a group of rare inherited inflammatory dis-
orders caused by different autosomal dominant mutations
in the cryopyrin-coding gene NLRP3 (nucleotide-binding
domain, leucine-rich repeat containing gene family, pyrin
domain containing protein 3) on chromosome 1q44, also
called CIAS1, PYPAF1 or NALP3. To date more than 90
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mutations associated with CAPS have been reported. Such
mutations lead to constitutive activation of caspase-1 and
subsequent abnormal IL-1β secretion. CAPS consists of a
spectrum of hereditary periodic fever syndromes that in-
clude familial cold autoinflammatory syndrome (FCAS;
OMIM/120100), Muckle-Wells Syndrome (MWS; OMIM/
191900), and chronic infantile neurological cutaneous and
articular syndrome (CINCA; OMIM/607115), also known
as neonatal-onset multisystem inflammatory disease
(NOMID). Clinically periodic fever and urticaria-like skin
lesions are hallmarks, and can be associated with one or
more of the following depending on severity: arthritis, con-
junctivitis, amyloidosis, sensorineural hearing loss, aseptic
meningitis and/or cerebral atrophy.
Interleukin-1 blockade has shown very good therapeutic
efficacy with rapid resolution of clinical symptoms and
complete normalisation of inflammatory markers such as
CRP. The recombinant IL-1 receptor antagonist anakinra
is currently the most used medication for the treatment of
CAPS. Canakinumab – a recombinant, fully human, mono-
clonal, anti-IL-1β antibody – and rilonacept – a dimeric
fusion protein consisting of the extracellular domains of
IL-1R1 and IL-1RAP joined to Fc domain of human IgG1
are effective alternative IL-1 inhibitors for this indication
[47–48].
Familial cold autoinflammatory syndrome
FCAS is the mildest form of CAPS and typically starts in
the first year of life. FCAS presents with recurrent attacks
of a maculopapular, painful, non-pruritic urticarial exan-
thema accompanied by fever, chills, joint stiffness, con-
junctivitis, and headache after exposure to cold [49]. The
urticarial rash begins 1–3 hrs after cold stimulus, peaks at
2–6 hrs and is accompanied by sweating. This seemingly
unprovoked sterile inflammation can result in neurosensory
deafness, intellectual impairment and meningitis [50].
Amyloidosis develops in fewer than 5% of patients.
The urticarial exanthema in CAPS patients is similar to that
observed in common urticaria. However, unlike in common
urticaria, anti-IL-1 therapy – rather than antihistamines –
results in complete remission of symptoms in patients suf-
fering from FCAS as long as the treatment is given.
Muckle-Wells syndrome
Muckle-Wells syndrome (MWS), also known as urticaria-
deafness-amyloidosis syndrome, has an intermediate sever-
ity among CAPS and was first reported in 1962. MWS is a
hereditary disease related to FCAS with recurrent episodes
of urticaria-like skin lesions appearing without cold expos-
ure [51]. MWS is also associated with late-onset neuro-
sensory deafness and renal amyloidosis occurring in 25%
of patients.
Chronic infantile neurological cutaneous and articular
syndrome
CINCA was first described in 1981 and is the most severe
form of CAPS. It occurs sporadically without a family his-
tory and typically starts during the neonatal period. Symp-
toms of CINCA include high fever, maculopapular or
urticaria-like, non-pruritic migratory exanthemas, arthro-
pathy, lymphadenopathy, hepatosplenomegaly and chronic
meningitis. CINCA is also associated with progressive loss
of vision and neurosensory deafness, and mental and
growth retardation. 20% of CINCA patients die within the
first two decades.
De novo mutations in NLRP3 can be found in only 50–60%
of patients [52–53]. Long-term efficacy of Kineret treat-
ment of patients suffering from CINCA has been reported
[54].
Other autoinflammatory diseases
Deficiency of interleukin-1 receptor antagonist
The recently reported deficiency of interleukin-1 receptor
antagonist (DIRA; OMIM/147679) is an autosomal recess-
ive inherited disease caused by mutations in IL1RN on
chromosome 2 leading to absence of IL-1RA and sub-
sequent IL-1 overactivity [55–56]. DIRA manifests itself
clinically with perinatal-onset pustular dermatitis, joint
swelling, painful osteolytic lesions and periosteitis. In con-
trast to CINCA, fever is rare and neurologic inflammation
is absent.
Treatment with anakinra – substituting the missing protein
in patients with its recombinant form – results in rapid clin-
ical improvement [57].
Table 1: Autoinflammatory disorders with skin involvement.
Disease Affected tissues Deficient molecule IL-1–targeting treatment Target molecule
CAPS
FCAS Skin, joints, eyes NLRP3 Anakinra
Rilonacept
Canakinumab
IL-1R1
IL-1β
IL-1β
MWS Skin, joints, eyes, ears, meninges NLRP3 Anakinra
Rilonacept
Canakinumab
IL-1R1
IL-1β
IL-1β
CINCA Skin, joints, eyes, ears, meninges and bones NLRP3 Anakinra
Canakinumab
IL-1R1
IL-1β
Other inflammatory disorders
DIRA Skin, bones, lungs, blood vessels IL-1RA Anakinra IL-1R1
PAPA syndrome Skin, joints PSTPIP1 Anakinra IL-1R1
Schnitzler syndrome Skin, joints, bones ? Anakinra IL-1R1
Sweet’s syndrome Skin ? Anakinra IL-1R1
Behcet’s disease Skin, eyes, mucosa, gastro-intestinal tract, nervous
system, blood vessels
IL-1β Anakinra IL-1R1
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Pyogenic arthritis-pyoderma gangrenosum-acne
syndrome
Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
(OMIM/604416), known as PAPA syndrome, is a rare in-
herited disorder caused by an autosomal dominant muta-
tion in PSTPIP1 (proline-serine-threonine-phosphatase in-
teractive protein 1) also known as CD2BP1 (CD2-binding
protein 1) on chromosome 15q24– q25.1 [58]. Although
presenting different clinical features, the pathophysiologies
of PAPA and FMF are related.
Sterile erosive arthritis especially of the knees, elbows and
ankles, usually starts in early childhood. Severe cystic acne
which can persist well into adulthood develops with pu-
berty, while arthritic symptoms tend to regress. Pyoderma
gangrenosum is variably expressed and manifests as poorly
healing ulcers preferentially developing on the distal limbs
but also in a multifocal fashion on the entire skin. In PAPA
syndrome patients, the regulation of caspase-1 activation is
lacking and increased production of IL-1β as well as tu-
mour necrosis factor (TNF) in peripheral blood mononuc-
lear cells has been reported [59–60].
The treatment of PAPA syndrome largely depends on the
dominant clinical manifestation. Anakinra has been shown
to be effective in controlling inflammatory lesions in PAPA
syndrome patients [61–62]. Infliximab (anti-TNF) has been
reported to be successful [63]. Arthritis episodes are usu-
ally successfully treated with cortisteroids. Pyoderma gan-
grenosum often responds poorly to systemic corticosteroids
and is therefore usually treated with immunosuppressants.
Schnitzler syndrome
Schnitzler syndrome usually presents in mid-adulthood
with non-pruritic urticaria-like exanthemas and IgM gam-
mopathy variably accompanied by fever, arthritis or arth-
ralgia, bone pain, lymphadenopathy and hepato- and/or
splenomegaly [64]. Both the exact aetiology and pathogen-
esis of Schnitzler syndrome remain to be clarified.
Therapies using antihistamines, non-steroidal antiinflam-
matory drugs, corticosteroids, immunosuppressive drugs,
colchicine, dapsone or thalidomide have shown very lim-
ited effects. TNF blockers have been shown to be ineffect-
ive. A mutation in NLRP3 has been reported in a single
case, suggesting possible involvement of the inflamma-
some in the pathogenesis [65]. Enhanced IL-1 secretion by
peripheral blood mononuclear cells has been demonstrated
in Schnitzler’s syndrome, and although the cause of this
has still to be identified, the recent evidence in favour of
clinical efficacy of anakinra and canakinumab in this syn-
drome suggest that IL-1β plays an important role in this
disease [66].
Sweet’s syndrome
Sweet’s syndrome was first reported in 1964 as an acute
febrile neutrophilic dermatosis [67]. Sweet's syndrome
(OMIM/608068) is a neutrophilic skin disease character-
ised by fever, an elevated neutrophil count, and painful
erythematous cutaneous nodules or plaques constituted his-
tologically by a diffuse dense infiltrate of mature neutro-
phils in the upper dermis. Sweet's syndrome is frequently
associated with haematological malignancies or chronic in-
flammatory disorders such as rheumatoid arthritis and in-
flammatory bowel disease, but may also occur in the ab-
sence of coexisting disease and is to date considered a
hypersensitivity reaction. A possible link with HLA-Bw54
is suspected in patients with Sweet’s syndrome, and high
levels of the cytokine G-CSF (granulocyte-colony stimu-
lating factor) have been demonstrated in the serum of pa-
tients. Furthermore, cases are reported where exogenous
G-CSF has triggered the disease, suggesting that this cy-
tokine, which promotes the production and survival of
neutrophils, plays a role in the pathogenesis of Sweet’s syn-
drome. Sweet syndrome does fulfil the current criteria for
classification as an autoinflammatory disease, notably the
seemingly unprovoked inflammation in the absence of de-
tectable autoantibodies and evidence of an antigen-specific
T-cell response.
Systemic corticosteroid therapy remains the gold standard
for the clinical management of patients with Sweet's syn-
drome. However, recently very encouraging responses to
Kineret administration have been reported, suggesting that
IL-1 and the inflammasome may play a significant role
in the pathophysiology of this autoinflammatory disease
[68–69].
Behçet's disease
Behçet's disease (BD, OMIM/109650) is a chronic system-
ic inflammatory disorder characterised by the following tri-
ad of symptoms: recurrent oral aphthous ulcers, genital ul-
cers, and uveitis [70]. BD is rare in Western countries but
more frequent in the Middle and Far East. The clinical con-
stellation of BD includes inflammatory lesions of muco-
cutaneous tissues (oral and genital ulceration, pseudofol-
liculitis, acne- and erythema nodosum-like skin lesions),
as well as ocular, vascular, digestive, and/or nervous sys-
tem tissues. The pathogenesis of BD is incompletely un-
derstood and is suggested to be of autoimmune aetiology,
although strong evidence for a causative autoantigen and
respective autoantibodies is lacking to date. Triggering of
an immune reaction by certain infectious agents that may
inhabit the oral cavity (Streptococcus and Staphylococcus
species, herpes simplex virus (HSV) and/or Escherichia
coli) has been suggested as playing a role in BD [71–72].
The systemic involvement of multiple organs, which can be
observed in BD, is based histopathologically on the devel-
opment of vasculitic lesions due to tissue infiltration with
both T cells and neutrophils. The presence of neutrophils
and the fact that BD is characterised by recurrent episodes
of inflammation without apparent cause open up the pos-
sibility that BD may be an autoinflammatory disease. In-
terestingly, among the predisposing genetic factors that are
considered to play an important role in the development
of BD are specific IL-1β gene polymorphisms that have
been reported to increase susceptibility to BD in the Turk-
ish population [73–74]. Furthermore, as in several diseases
considered to be autoinflammatory to date, excellent clinic-
al responses have been reported in BD patients treated with
Kineret, reinforcing the possibility of a role for IL-1 in the
pathogenesis of BD [75–76].
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Conclusion
While being a key player in innate immune responses, re-
cent evidence has clearly demonstrated that in certain in-
stances IL-1β overproduction may be the cause, or be as-
sociated with several more or less severe inflammatory
diseases, several of which have recently been classified as
autoinflammatory diseases and are associated with skin le-
sions. This relatively new group of diseases is considered
to be distinct from autoimmune and allergic diseases, in
that both the presence of autoantibodies and evidence of an
antigen-specific T-cell response which characterise the lat-
ter are absent in the former. The discovery of the inflam-
masomes as key intracellular sensing complexes required
for IL-1 secretion has opened the way to elucidation of
the pathomechanisms involved in autoinflammation, cer-
tain autoinflammatory diseases, and several inflammatory
skin diseases caused by external environmental factors.
These diseases have in common their recurrent inflammat-
ory nature, multisytemic involvement, the skin as a fre-
quently involved organ, and the frequent contribution of
neutrophils to the inflammatory lesions observed. The new
understanding of the role of the inflammasome and IL-1
in an emerging set of diseases has led the successful de-
velopment and implementation in clinical trials of ther-
apies targeted against IL-1 for autoinflammatory diseases,
prime examples of which are the use of IL-1 antagonists in
cryopyrin-associated periodic syndromes such as Muckle-
Wells syndrome.
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Figures (large format)
Figure 1
The inflammasomes. Several types of inflammasomes have been described. Upon exposure to specific PAMPs/DAMPs, respective
inflammasomes are activated, leading to the proteolytic cleavage of caspase-1 or -5 (CASP) and subsequent cleavage of pro-IL1β into its
active, secreted form.
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Figure 2
Current models of inflammasome activation involve K+ efflux, release of reactive oxygen species (ROS) and mitochondrial DNA (mtDNA) in the
cytosol. Upon encounter of PAMPs/DAMPs including microbes or crystals, the NLRP3–inflammasome is activated and the resulting IL-1β
release triggers localised inflammatory responses. In contrast, the NLRP3–inflammasome is constitutively activated, resulting in multi-organ
involvement and periodic fever in patients suffering from autoinflammatory disorders.
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